Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1984-12-18
|
| pubmed:abstractText |
Prostacyclin (PGI2) has been suggested for use in cardiopulmonary bypass (CPB) because of its positive effects on platelet number and function. Fifty patients who underwent coronary artery bypass grafting using a bubble oxygenator received heparin, 3 mg per kilogram of body weight, and then were randomly assigned to receive PGI2, 25 ng/kg/min, beginning 5 minutes before and until the end of CPB (26 patients) or a placebo (24 patients). Both groups were similar in sex, age, heparin dose, protamine dose, and CPB time. During CPB, mean arterial pressure fell significantly with PGI2 (76 +/- 2 mm Hg to 53 +/- 2 mm Hg; p less than 0.05) and necessitated pressor substances. Platelet counts fell significantly in both groups with the start of CPB, but after 60 minutes were similar in both groups (118 +/- 9 X 10(3) versus 130 +/- 8 X 10(3); not significant [NS]) and were unchanged 3 hours after CPB. Total chest tube output was 647 +/- 51 ml (placebo group) versus 576 +/- 34 ml (PGI2 group) (NS); 18 of the patients given PGI2 required 26 transfusions compared with 16 transfusions in 8 of the patients given a placebo (p less than 0.05). In PGI2 patients, arterial oxygen tension on 100% oxygen fell from 281 +/- 18 mm Hg before CPB to 223 +/- 17 mm Hg immediately after CPB (p less than 0.05). The placebo patients did not show a change in this variable.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-Ketoprostaglandin F1 alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Oxygen,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0003-4975
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
514-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6388516-6-Ketoprostaglandin F1 alpha,
pubmed-meshheading:6388516-Blood Pressure,
pubmed-meshheading:6388516-Blood Transfusion,
pubmed-meshheading:6388516-Cardiopulmonary Bypass,
pubmed-meshheading:6388516-Clinical Trials as Topic,
pubmed-meshheading:6388516-Coronary Artery Bypass,
pubmed-meshheading:6388516-Double-Blind Method,
pubmed-meshheading:6388516-Epoprostenol,
pubmed-meshheading:6388516-Female,
pubmed-meshheading:6388516-Heparin,
pubmed-meshheading:6388516-Humans,
pubmed-meshheading:6388516-Infusions, Parenteral,
pubmed-meshheading:6388516-Male,
pubmed-meshheading:6388516-Middle Aged,
pubmed-meshheading:6388516-Oxygen,
pubmed-meshheading:6388516-Platelet Count,
pubmed-meshheading:6388516-Random Allocation,
pubmed-meshheading:6388516-Thromboxane B2,
pubmed-meshheading:6388516-Vasoconstrictor Agents
|
| pubmed:year |
1984
|
| pubmed:articleTitle |
Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|